Novo, Pfizer and Nan Fung helped provide $93.5m for the cancer treatment developer as it advances its lead product candidate towards the clinic.
US-based cancer therapy developer Bolt Biotherapeutics closed a $93.5m series C round yesterday backed property development group Nan Fung and pharmaceutical firms Pfizer and Novo.
Venture capital firm Sofinnova Investments led the round, which also featured RA Capital Management, Surveyor Capital, Rock Springs Capital, Samsara BioCapital, Vivo Capital and undisclosed additional investors.
Pfizer invested in the round through its corporate venture capital arm, Pfizer Ventures, while Nan Fung took part through life science investment vehicle Pivotal BioVenture Partners.
Spun out…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
